Synapse - Gopakumar Iyer

Results (352)

Clinical, molecular and immunohistochemical profiles of clear cell adenocarcinoma of the urinary tract

Meeting Abstract

Koll, F.; Rammal, R.; Chen, Z.; Basar, M.; Alam, S. M.; Tallman, J. E.; Pietzak, E.; Dalbagni, G.; Donahue, T.; Donat, S. M.; more...
Urologic Oncology: Seminars and Original Investigations (2024)

Fulltext@MSK | Save

Carcinoma in situ and urinary cytology as an indicator of minimal residual disease in patients with non-muscle invasive bladder cancer treated with BCG

Meeting Abstract

Katims, A. B.; D'Souza, N.; De Jesus Escaño, M. R.; Gokturk, G.; Basar, M.; Solit, D. B.; Iyer, G.; Bochner, B. H.; Goh, A.; Donahue, T. A.; more...
Urologic Oncology: Seminars and Original Investigations (2024)

Fulltext@MSK | Save

Comutational patterns in FGFR3-altered non-muscle invasive bladder cancer influence recurrence and progression

Meeting Abstract

D'Souza, N.; de Jesus Escano, M.; Alam, S. M.; Gao, S.; Tang, X.; Goh, A.; Bochner, B. H.; Solit, D.; Iyer, G.; Al-Ahmadie, H.; more...
Urologic Oncology: Seminars and Original Investigations (2024)

Fulltext@MSK | Save

Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer

Journal Article

Powles, T.; Valderrama, B. P.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
New England Journal of Medicine (2024)

Fulltext@MSK | Save

First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations

Journal Article

Janku, F.; Kim, T. M.; Iyer, G.; Spreafico, A.; Elez, E.; de Jonge, M.; Yamamoto, N.; van der Wekken, A. J.; Ascierto, P. A.; Maur, M.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV + P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Meeting Abstract

Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Meeting Abstract

Powles, T. B.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial

Meeting Abstract

Loriot, Y.; Pant, S.; Witt, O.; Reardon, D. A.; Doi, T.; Qin, S.; Tabernero, J.; Iyer, G.; Massard, C.; Arnold, D.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)